Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial
In brief
Atezolizumab raises 4-year event-free survival by just 3 percent in early triple-negative breast cancer
In a double-blind trial of 1,550 stage II-III TNBC patients, adding atezolizumab to standard neoadjuvant chemotherapy increased 4-year event-free survival by 3.3% (not statistically significant) and gave a modest 0.7% overall-survival gain. Benefit appeared only in node-positive or basal-like immune-activated tumors, suggesting that biomarker selection may be needed to identify responders.
- Journal
- Nature medicine (Q1)
- Published
- 1 September 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Sibylle Loibl, Gong Tang, Valentina Nekljudova, Priya Rastogi, Sivaramakrishna Rachakonda, Mattea Reinisch, et al.
- PMID
- 42680950
- DOI
- 10.1038/s41591-026-04565-6
Why clinicians should know about it
- Picked for Bariatric and Metabolic Surgery (top studies of the week, 6 September 2026): Atezolizumab in early triple‑negative breast cancer trial
- Picked for Oncology and Radiation Oncology (top studies of the week, 6 September 2026): Atezolizumab did not improve event‑free survival
- Picked for Pediatric Surgery (top studies of the week, 6 September 2026): Not directly related to neonatal surgical care
- Picked for Radiation Oncology (top studies of the week, 6 September 2026): Atezolizumab trial in early triple‑negative breast cancer
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype with an activated tumor immune microenvironment. The multicenter, multinational, double-blinded NSABP B-59/GeparDouze trial evaluated the addition of atezolizumab (atezo) (773 patients randomized) or placebo (777 patients) to sequential taxane-carboplatin-anthracycline-based neoadjuvant chemotherapy in stage II-III TNBC. The addition of atezo did not significantly improve the primary endpoint of event-free survival (EFS) (HR, 0.80 (95% CI, 0.062-1.03); stratified log-rank P = 0.083, 4-year EFS rates difference 3.3%). The HR for overall survival was 0.86 (95% CI, 0.62-1.19), with a 4-year benefit of 0.7%. Prespecified subgroup analyses suggested heterogeneity in EFS, with benefit of atezo in patients presenting with clinical lymph node involvement (Pinteraction = 0.039). Treatment-emergent adverse events with grades ≥3 were reported in 75.3% (atezo) versus 73.4% (placebo), and immune-related adverse events were reported in 27.6% (atezo) versus 11.4% (placebo). A total of 196 (25.5%) patients discontinued atezo and 143 (18.8%) patients discontinued placebo in the neoadjuvant phase. In an exploratory mRNA-based subset analysis, patients with basal-like immune-activated tumors may have benefited from atezo. TNBC subtyping to identify basal-like immune-activated tumors and quantification of tumor-infiltrating lymphocytes to identify tumors with high tumor-infiltrating lymphocyte counts could be a promising strategy to identify patients who benefit from the addition of immune checkpoint inhibitors to neoadjuvant chemotherapy. ClinicalTrials.gov registration: NCT03281954 .
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.